Dynamic single-cell RNA sequencing identifies immunotherapy persister cells following PD-1 blockade
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Resistance to oncogene-targeted therapies involves discrete drug-tolerant persister cells, originally discovered through in vitro assays. Whether a similar phenomenon limits efficacy of programmed cell death 1 (PD-1) blockade is poorly understood. Here, we performed dynamic single-cell RNA-Seq of murine organotypic tumor spheroids undergoing PD-1 blockade, identifying a discrete subpopulation of immunotherapy persister cells (IPCs) that resisted CD8+ T cell-mediated killing. These cells expressed Snai1 and stem cell antigen 1 (Sca-1) and exhibited hybrid epithelial-mesenchymal features characteristic of a stem cell-like state. IPCs were expanded by IL-6 but were vulnerable to TNF-α-induced cytotoxicity, relying on baculoviral IAP repeat-containing protein 2 (Birc2) and Birc3 as survival factors. Combining PD-1 blockade with Birc2/3 antagonism in mice reduced IPCs and enhanced tumor cell killing in vivo, resulting in durable responsiveness that matched TNF cytotoxicity thresholds in vitro. Together, these data demonstrate the power of high-resolution functional ex vivo profiling to uncover fundamental mechanisms of immune escape from durable anti-PD-1 responses, while identifying IPCs as a cancer cell subpopulation targetable by specific therapeutic combinations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106
Scenic: single-cell regulatory network inference and clustering.
Aibar, S., González-Blas, C. B., Moerman, T., Huynh-Thu, V. A., Imrichova, H., Hulselmans, G., Rambow, F., Marine, J.-C., Geurts, P., Aerts, J., et al. (2017) · Nature Methods · doi:10.1038/nmeth.4463 · Cited by 6,520
New insights into the mechanisms of epithelial–mesenchymal transition and implications for cancer
Dongre, A., & Weinberg, R. A. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-018-0080-4 · Cited by 3,876
Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
Zaretsky, J. M., Garcia-Diaz, A., Shin, D. S., Escuin-Ordinas, H., Hugo, W., Hu-Lieskovan, S., Torrejon, D. Y., Abril-Rodriguez, G., Sandoval, S., Barthly, L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1604958 · Cited by 3,237 · cited 1×
“In addition, IPCs downregulate IFN response, which has been associated with resistance to 335 ICB in multiple studies (33, 35-37).”
BackgroundA Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
Sharma, S. V., Lee, D. Y., Li, B., Quinlan, M. P., Takahashi, F., Maheswaran, S., McDermott, U., Azizian, N., Zou, L., Fischbach, M. A., et al. (2010) · Cell · doi:10.1016/j.cell.2010.02.027 · Cited by 2,770
EMT, CSCs, and drug resistance: the mechanistic link and clinical implications
Shibue, T., & Weinberg, R. A. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.44 · Cited by 2,539 · cited 1×
“Features of EMT have also been linked with a tumor-initiating, stem cell-like state in 80 cancer (13, 14).”
BackgroundTumor and Microenvironment Evolution during Immunotherapy with Nivolumab
Riaz, N., Havel, J. J., Makarov, V., Desrichard, A., Urba, W. J., Sims, J. S., Hodi, F. S., Martín-Algarra, S., Mandal, R., Sharfman, W. H., et al. (2017) · Cell · doi:10.1016/j.cell.2017.09.028 · Cited by 2,401 · cited 1×
“28 Human anti-PD-1 RNA-sequencing dataset 600 Bulk RNAseq data from pre-treatment samples were obtained from the Riaz cohort (57).”
MethodThe evolving landscape of biomarkers for checkpoint inhibitor immunotherapy
Havel, J. J., Chowell, D., & Chan, T. A. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0116-x · Cited by 2,286 · cited 1×
“191 Similar to syngeneic murine models such as MC38, microsatellite instability-high (MSI192 H) status in patient tumors is a robust predictive biomarker for response to anti-PD-1 therapy in 193 the clinic (23).”
BackgroundTumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion
Straussman, R., Morikawa, T., Shee, K., Barzily-Rokni, M., Qian, Z. R., Du, J., Davis, A., Mongare, M. M., Gould, J., Frederick, D. T., et al. (2012) · Nature · doi:10.1038/nature11183 · Cited by 1,771 · cited 1×
“were upregulated in bulk RNA-seq data following αPD-1 treatment and have been implicated in 246 resistance to oncogene-targeted therapies (27, 28).”
BackgroundMouse genomic variation and its effect on phenotypes and gene regulation.
Keane, T. M., Goodstadt, L., Danecek, P., White, M. A., Wong, K., Yalcin, B., Heger, A., Agam, A., Slater, G., Goodson, M., et al. (2011) · Nature · doi:10.1038/nature10413 · Cited by 1,580
Research works printed but not linked: 36
- 10.1038/s41573-019-0044-1 · DOI · Paper page
- 10.1016/j.bbcan.2018.10.003 · DOI · Paper page
- 10.1158/2159-8290.CD-17-0461 · DOI · Paper page
- 10.1158/0008-5472.CAN-17-1904 · DOI · Paper page
- 10.1016/j.trecan.2018.07.003 · DOI
- 10.1093/annonc/mdw041 · DOI · Paper page
- 10.1016/j.celrep.2017.11.052 · DOI · Paper page
- 10.1016/j.jtho.2017.04.017 · DOI · Paper page
- 10.1016/j.cell.2008.03.027 · DOI · Paper page
- 10.1038/s12276-018-0071-8 · DOI · Paper page
- 10.1038/s41598-019-45934-1 · DOI
- 10.1073/pnas.1812876116 · DOI · Paper page
- 10.1016/j.cell.2005.03.032 · DOI · Paper page
- 10.1158/2326-6066.CIR-18-0683 · DOI · Paper page
- 10.1016/j.stemcr.2017.04.012 · DOI · Paper page
- 10.1158/2159-8290.CD-12-0237 · DOI · Paper page
- Nichols, 2001, Physiological rationale for responsiveness of mouse embryonic stem cells to gp130 cytokines, Development, 128, 2333, 10.1242/dev.128.12.2333 · DOI · Paper page
- 10.1002/stem.252 · DOI · Paper page
- 10.1158/1078-0432.CCR-16-2172 · DOI
- 10.1126/science.1071924 · DOI · Paper page
- 10.1016/j.cell.2019.06.014 · DOI · Paper page
- 10.1371/journal.pone.0066558 · DOI · Paper page
- 10.1038/s41598-018-27021-z · DOI
- 10.1038/s41586-019-1340-y · DOI · Paper page
- 10.1634/stemcells.2006-0644 · DOI · Paper page
- 10.1158/0008-5472.CAN-15-2654 · DOI · Paper page
- 10.1002/stem.188 · DOI · Paper page
- 10.1172/JCI44745 · DOI · Paper page
- Wang, 2018, IL-6 mediates platinum-induced enrichment of ovarian cancer stem cells, JCI Insight, 3, 10.1172/jci.insight.122360 · DOI
- 10.1111/cas.12937 · DOI
- 10.1038/cdd.2017.183 · DOI · Paper page
- 10.1038/nm.4040 · DOI · Paper page
- 10.1089/omi.2011.0118 · DOI · Paper page
- 10.1093/bioinformatics/btz479 · DOI
- Zeitouni, 2017, Whole-exome somatic mutation analysis of mouse cancer models and implications for preclinical immunomodulatory drug development, Cancer Research, 77
- 10.1016/j.jtho.2016.09.002 · DOI · Paper page
Cited by
RNA sequencing: new technologies and applications in cancer research
Hong, M., Tao, S., Zhang, L., Diao, L.-T., Huang, X., Huang, S., Xie, S.-J., Xiao, Z.-D., & Zhang, H. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-01005-x · Cited by 596
Loh, J.-J., & Ma, S. (2024) · Cell Stem Cell · doi:10.1016/j.stem.2024.04.004 · Cited by 314
Cancer drug-tolerant persister cells: from biological questions to clinical opportunities
Russo, M., Chen, M., Mariella, E., Peng, H., Rehman, S. K., Sancho, E., Sogari, A., Toh, T. S., Balaban, N. Q., Batlle, E., et al. (2024) · Nature Reviews Cancer · doi:10.1038/s41568-024-00737-z · Cited by 210
Current and future perspectives of PD-1/PDL-1 blockade in cancer immunotherapy
Makuku, R., Khalili, N., Razi, S., Keshavarz-Fathi, M., & Rezaei, N. (2021) · Journal of Immunology Research · doi:10.1155/2021/6661406 · Cited by 136
Fighting Drug Resistance through the Targeting of Drug-Tolerant Persister Cells
De Conti, G., Dias, M. H., & Bernards, R. (2021) · Cancers · doi:10.3390/cancers13051118 · Cited by 111
“However, a recent study described the emergence of a discrete subpopulation of cells resistant to an immune-checkpoint inhibitor (anti-PD1 antibody) in a murine organotypic spheroid ex vivo model [44].”
Background
Metadata
- Authors
- Sehgal, K., Portell, A., Ivanova, E. V., Lizotte, P. H., Mahadevan, N. R., Greene, J. R., Vajdi, A., Gurjao, C., Teceno, T., Taus, L. J., Thai, T. C., Kitajima, S., Liu, D., Tani, T., Noureddine, M., Lau, C. J., Kirschmeier, P. T., Liu, D., Giannakis, M., Jenkins, R. W., Gokhale, P. C., Goldoni, S., Pinzon-Ortiz, M., Hastings, W. D., Hammerman, P. S., Miret, J. J., Paweletz, C. P., & Barbie, D. A.
- Venue
- Journal of Clinical Investigation
- Published
- 2021-01-19
- Volume
- 131
- Issue
- 2
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- OpenAlex
- W3097030583
- Cited by
- 74
- References
- 25
- FWCI
- 2.73
- Type
- journal article
- Language
- en
- Open access
- bronze
- Funders
- National Cancer Institute (R01 CA190394-04, K08CA226391)
- National Institute of Health (U01 CA2143A1-02)
- NIBR-DFCI (Drug Discovery, Translational Program)
- Heerwagen, Gross-Loh Family Funds for Lung Cancer Research (Research)
- Candice Bagby Fund (Research)
- Robert and Renée Belfer Center for Applied Cancer Science (Research)
- Expect Miracles (Research)
- ASCO (Career Development Award)
- SU2C-AACR (DT22-17)
- National Institutes of Health (R01CA166480, K08CA234458)
- Society for Immunotherapy of Cancer (SITC)
- Parker Foundation (Parker Institute for Cancer Immunotherapy Pilot Award)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Dynamic single-cell RNA sequencing identifies immunotherapy persister cells following PD-1 blockade. https://app.cochat.ai/papers/10.1172/jci135038
- The paper
- Sehgal, K., Portell, A., Ivanova, E. V., Lizotte, P. H., Mahadevan, N. R., Greene, J. R., Vajdi, A., Gurjao, C., Teceno, T., Taus, L. J., Thai, T. C., Kitajima, S., Liu, D., Tani, T., Noureddine, M., Lau, C. J., Kirschmeier, P. T., Liu, D., Giannakis, M., . . . Barbie, D. A. (2021). Dynamic single-cell RNA sequencing identifies immunotherapy persister cells following PD-1 blockade. Journal of Clinical Investigation. https://doi.org/10.1172/jci135038
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.